VIDEO: Ponatinib dose-optimization beneficial for CML despite cardiac toxicity
Click Here to Manage Email Alerts
In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed a pair of abstracts that looked at the use of ponatinib for Philadelphia chromosome positive ALL and resistant CML. One study looked at dose optimization of ponatinib for patients with CML, which indicated that starting treatment with a higher dose and then titrating down was effective.
"While they showed you need a relatively higher dose of ponatinib to start, you can go down to 30 mg and still see benefit in T315 patients and then titrate down further as you deepen the molecular response," said Byrd.
"For a drug that has a narrower therapeutic window than we want for cardiac toxicity, that is beneficial," he said.
Collapse
Click Here to Manage Email Alerts